Sarah E. M. Herman

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

Sarah E. M. Herman, Amber Gordon, Erin Hertlein et al. · Blood · 2011 · 789 citations · Full text

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Mohammed Farooqui, Janet Valdez, Sabrina Martyr et al. · The Lancet Oncology · 2014 · 365 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Tp53 Aberrations +8

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Inhye E. Ahn, Chingiz Underbayev, Adam Albitar et al. · Blood · 2017 · 336 citations · Full text

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

Sarah E. M. Herman, Rashida Z. Mustafa, Jennifer Gyamfi et al. · Blood · 2014 · 240 citations · Full text

Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib

Clare Sun, Xin Tian, Yuh Shan Lee et al. · Blood · 2015 · 218 citations · Full text